Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand.
Background
- Client since 2017
- AIM listed company providing specialist pharmacovigilance and CRO services to the global pharmaceutical industry
Consilium’s Strategy
- Ongoing strategic advice and positioning of investment case as a full services business, amplification of significant news flow including multiple deals:
- Acquisition of ADAMAS in February 2022
- Provision of services to multiple COVID-19 trials
- Acquisition of MedSource in December 2020
- Strategic work for financial reporting and M&A and increasing awareness and visibility across business and investor media and retail investors
Outcome
- Successfully positioned investment case across all communications
- Relationships strengthened across media with high quality and strategically-placed coverage
- Increased awareness and understanding of business in the City amongst analysts and investors
- Strengthened retail investor awareness of the company at investor event webinars